PDCD1 and neoplasm: In BALB/c mice bearing CT26 colorectal cancer tumours (Fig. 8j), NIL-IM-Lip+PD-1+L showed stronger antitumour efficacy and a similar immune response to those observed in the B16F10 model (Fig. 8k–r).